CTNM Q2 2024 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena

CTNMContineum Therapeutics, Inc. Class A Common Stock

$504M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$11M

Net Income

-$9M

EPS (Diluted)

$-0.35

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$221M

Total Liabilities

$4M

Stockholders' Equity

$218M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$50M	-100.0%
Gross Profit	$0	$50M	-100.0%
Operating Income	-$11M	$39M	-128.1%
Net Income	-$9M	$42M	-121.7%